Investment Thesis
Kura Oncology is a clinical-stage pharmaceutical company with critical financial distress: $39.1M cash against $85.9M annual operating cash burn creates a sub-6-month runway requiring immediate financing. Despite 25.2% YoY revenue growth, absolute revenue of $18.3M is dwarfed by operating losses of $78.8M, resulting in -401.5% net margin and destroying shareholder value at -68.0% ROE.
Strengths
- Low financial leverage with 0.09x Debt/Equity ratio minimizes bankruptcy risk from debt obligations
- Positive revenue growth of 25.2% YoY indicates early commercial traction or milestone progress
- Strong liquidity ratios (6.15x current ratio) suggest operational cash management capability despite burn
Risks
- Critical cash runway of less than 6 months at current $85.9M annual operating burn rate
- Existential financial distress: $73.3M net loss with no visible profitability path from current operations
- Biotech clinical/regulatory risk inherent to oncology R&D with uncertain commercialization timeline and success probability
Key Metrics to Watch
- Quarterly operating cash flow and cash balance depletion rate
- Financing activity and debt equity raises urgency and dilution magnitude
- Product revenue acceleration and gross margin expansion on commercial programs
Financial Metrics
Revenue
18.3M
Net Income
-73.3M
EPS (Diluted)
$-0.83
Free Cash Flow
-86.0M
Total Assets
652.6M
Cash
39.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-431.5%
Net Margin
-401.5%
ROE
-68.0%
ROA
-11.2%
FCF Margin
-470.7%
Balance Sheet & Liquidity
Current Ratio
6.15x
Quick Ratio
6.14x
Debt/Equity
0.09x
Debt/Assets
83.5%
Interest Coverage
-98.03x
Long-term Debt
9.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:25:21.909465 |
Data as of: 2026-03-31 |
Powered by Claude AI